×
About 14,354 results

ALLMedicine™ Purpura Center

Research & Reviews  6,853 results

Spontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TT...
https://doi.org/10.1080/16078454.2020.1848973
Hematology (Amsterdam, Netherlands); Browning S, Bahar B et. al.

Dec 3rd, 2020 - Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy that can have high mortality rates without prompt treatment. Standard treatment is urgent plasma exchange (PLEX), which leads to disease remission in the vast majority of pa...

Multicentric evaluation of the new HemosIL Acustar® chemiluminescence ADAMTS13 activity...
https://doi.org/10.1111/ijlh.13414
International Journal of Laboratory Hematology REFERENCES; Pascual C, Nieto JM et. al.

Dec 2nd, 2020 - Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening thrombotic microangiopathy (TMA) characterized by the severe deficiency of ADAMTS13 activity (<10%). Rapid ADAMTS13 testing is crucial for early diagnosis and optimal management ...

Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pi...
https://doi.org/10.1016/j.jaut.2020.102577
Journal of Autoimmunity; Saadoun D, Ghembaza A et. al.

Nov 29th, 2020 - To report the efficacy of rituximab plus belimumab in patients with refractory cryoglobulinemia vasculitis (CV). Belimumab was administered intravenously at a dose of 10 mg/kg on days 0, 14, 28 and then every month in association with rituximab in...

Numerous schistocytes in thrombotic thrombocytopenic purpura.
https://doi.org/10.1136/postgradmedj-2020-139308
Postgraduate Medical Journal; Kunitomo K, Hirano T et. al.

Nov 25th, 2020 - Numerous schistocytes in thrombotic thrombocytopenic purpura.|2020|Kunitomo K,Hirano T,Tsuji T,|

Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive ca...
https://doi.org/10.1111/jth.15194
Journal of Thrombosis and Haemostasis : JTH; Picod A, Veyradier A et. al.

Nov 25th, 2020 - Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disease that causes systemic platelet-rich microthrombi with multiorgan damage. The historical treatment is based on therapeutic plasma exchange (TPE) and immun...

see more →

Guidelines  17 results

European consensus-based recommendations for diagnosis and treatment of immunoglobulin ...
https://doi.org/10.1093/rheumatology/kez041
Rheumatology (Oxford, England); Ozen S, Marks SD et. al.

Mar 17th, 2019 - IgA vasculitis (IgAV, formerly known as Henoch-Schönlein purpura) is the most common cause of systemic vasculitis in childhood. To date, there are no internationally agreed, evidence-based guidelines concerning the appropriate diagnosis and treatm...

CABLIVI (caplacizumab-yhdp) Prescribing Information
http://products.sanofi.us/cablivi/cablivi.pdf

Feb 5th, 2019 - CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

FDA approves Cablivi, first treatment for acquired thrombotic thrombocytopenic purpura
https://www.healio.com/hematology-oncology/hematology/news/online/%7Be91d83f6-8859-412b-970c-198151f0b208%7D/fda-approves-cablivi-first-treatment-for-acquired-thrombotic-thrombocytopenic-purpura
Pazdur,R.

Feb 5th, 2019 - The FDA today approved caplacizumab-yhdp injection as the first therapy specifically indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura, a rare and life-threatening blood clotting disorder.

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
http://hugin.info/152918/R/2233733/878824.pdf

Feb 5th, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the firs...

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
https://www.nejm.org/doi/10.1056/NEJMoa1806311
Scully,M.,et al

Jan 23rd, 2019 - In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which re...

see more →

Drugs  51 results see all →

Clinicaltrials.gov  7,053 results

Spontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TT...
https://doi.org/10.1080/16078454.2020.1848973
Hematology (Amsterdam, Netherlands); Browning S, Bahar B et. al.

Dec 3rd, 2020 - Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy that can have high mortality rates without prompt treatment. Standard treatment is urgent plasma exchange (PLEX), which leads to disease remission in the vast majority of pa...

Multicentric evaluation of the new HemosIL Acustar® chemiluminescence ADAMTS13 activity...
https://doi.org/10.1111/ijlh.13414
International Journal of Laboratory Hematology REFERENCES; Pascual C, Nieto JM et. al.

Dec 2nd, 2020 - Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening thrombotic microangiopathy (TMA) characterized by the severe deficiency of ADAMTS13 activity (<10%). Rapid ADAMTS13 testing is crucial for early diagnosis and optimal management ...

Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pi...
https://doi.org/10.1016/j.jaut.2020.102577
Journal of Autoimmunity; Saadoun D, Ghembaza A et. al.

Nov 29th, 2020 - To report the efficacy of rituximab plus belimumab in patients with refractory cryoglobulinemia vasculitis (CV). Belimumab was administered intravenously at a dose of 10 mg/kg on days 0, 14, 28 and then every month in association with rituximab in...

Numerous schistocytes in thrombotic thrombocytopenic purpura.
https://doi.org/10.1136/postgradmedj-2020-139308
Postgraduate Medical Journal; Kunitomo K, Hirano T et. al.

Nov 25th, 2020 - Numerous schistocytes in thrombotic thrombocytopenic purpura.|2020|Kunitomo K,Hirano T,Tsuji T,|

Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive ca...
https://doi.org/10.1111/jth.15194
Journal of Thrombosis and Haemostasis : JTH; Picod A, Veyradier A et. al.

Nov 25th, 2020 - Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disease that causes systemic platelet-rich microthrombi with multiorgan damage. The historical treatment is based on therapeutic plasma exchange (TPE) and immun...

see more →

News  347 results

Low Threshold to Biopsy Atypical Lesions May ID Vulvar Melanoma Early, Experts Say
https://www.staging.medscape.com/viewarticle/941157

Nov 16th, 2020 - Having a low threshold to biopsy atypical pigmented lesions on the vulva may identify melanoma early, according to a lecture at virtual conference on diseases of the vulva and vagina, hosted by the International Society for the Study of Vulvovagin...

Low Threshold to Biopsy Atypical Lesions May ID Vulvar Melanoma Early, Experts Say
https://www.medscape.com/viewarticle/941157

Nov 16th, 2020 - Having a low threshold to biopsy atypical pigmented lesions on the vulva may identify melanoma early, according to a lecture at virtual conference on diseases of the vulva and vagina, hosted by the International Society for the Study of Vulvovagin...

NICE Recommends Innovative Treatment for Severe Blood Disorder for NHS Use
https://www.medscape.com/viewarticle/941022

Nov 15th, 2020 - A brand-new treatment – one of the first for 25 years – for acute acquired thrombotic thrombocytopenic purpura (aTTP) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine use in the NHS. Caplacizumab (Ca...

Skin Symptoms Common in COVID 'Long-Haulers'
https://www.staging.medscape.com/viewarticle/940058

Oct 29th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. A small subset of SARS-CoV-2 patients with "COVID toes" can be categorized as COVID long-haulers, with skin symptoms sometimes enduring for more t...

Pediatric Dermatology Emergencies
https://www.mdedge.com/dermatology/article/218463/pediatrics/pediatric-dermatology-emergencies/page/0/3?channel=271

Mar 5th, 2020 - IgA Vasculitis Presentation IgA vasculitis, or Henoch-Schönlein purpura, classically presents as a tetrad of palpable purpura, acute-onset arthritis or arthralgia, abdominal pain, and renal disease with proteinuria or hematuria. 30 Skin involvement.

see more →

Patient Education  33 results see all →